Mounjaro age limit: what the UK licence says and why it matters

What the clinical trials tell us about Mounjaro's licensed age range

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled thousands of adults with obesity and no diabetes. Its participants were 18 and older, which is exactly the population Mounjaro's UK weight-management licence covers. The trial was not designed to test tirzepatide in adolescents, and no paediatric weight-management indication has been granted in the UK. That is the evidential reason the lower boundary sits at 18: the data simply do not extend below it.

There is a common assumption that these medicines carry an upper age cut-off too — perhaps 65, or 70. They do not. The UK SmPC does not specify a maximum age. What it does say is that older patients may need closer monitoring, particularly around dehydration risk during the early weeks when gastrointestinal side effects are most noticeable. A prescriber reviewing someone in their seventies will look carefully at kidney function, existing medicines, and cardiovascular history, not tick a box because a certain birthday has passed. You can read the NHS patient information for tirzepatide for a plain-English account of how the medicine is used and who it is suitable for.

For anyone researching the full picture on Mounjaro before a consultation, understanding the licence is the right starting point. Age is one filter among several, and rarely the decisive one for adults.

Why under-18s cannot be prescribed Mounjaro for weight management

Prescribing a medicine outside its licensed age range (for a child or teenager) is possible in principle under UK law in certain clinical circumstances, but it requires specialist oversight and a specific clinical rationale. For weight management, no such pathway exists for tirzepatide in the UK at present. The manufacturer has not submitted paediatric trial data for this indication, and the MHRA has not granted a licence covering under-18s.

This matters because parents sometimes enquire on behalf of teenagers struggling with their weight. The instinct to help is entirely understandable. However, the appropriate route for a young person in that situation is a referral to a specialist paediatric or adolescent service through their GP, not an online weight-loss pharmacy. If you have questions about what pathways exist for younger family members, a conversation with a GP is the right first step.

The tirzepatide and age page goes into more detail on how the age boundary interacts with the wider eligibility criteria, including BMI thresholds and weight-related conditions.

Older adults: what prescribers consider beyond the age itself

Age-related physiology does affect how some medicines behave. Kidney clearance slows with age; the risk of dehydration rises when nausea or vomiting occurs in the early weeks of treatment. These are real clinical considerations, not reasons to dismiss older adults from the conversation. In SURMOUNT-1, participants ranged widely in age, and meaningful weight reduction was observed across the adult age spectrum.

A prescriber reviewing an older patient will typically focus on four things: existing kidney and liver function, which other medicines are being taken (interactions matter more when a patient is on several long-term drugs), cardiovascular status, and whether the patient can manage an injectable treatment safely at home. None of these factors disqualify by default. They inform the dose-titration plan and the monitoring schedule.

There is a related question some readers raise: does Mounjaro affect how you look or age over time, particularly with significant weight loss? That is a separate question from the age-limit one, and the does Mounjaro age you page addresses it directly. For cost considerations relevant to longer-term treatment, the Mounjaro prices guide sets out what private treatment typically involves.

How the minimum age interacts with the rest of the eligibility picture

Meeting the age criterion (being 18 or over) is necessary but not sufficient. The UK licence requires a BMI of at least 30, or at least 27 with one or more weight-related health conditions such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Pregnancy, breastfeeding, or planning to become pregnant rules out treatment: Mounjaro is not recommended in any of these situations.

NICE's appraisal of tirzepatide, TA1026, sets tighter criteria for NHS access, a higher BMI floor and multiple comorbidities. Private prescribing follows the licensed criteria rather than NICE's NHS commissioning thresholds, which is one reason private treatment is available to a broader group of adults who still meet the SmPC's clinical criteria. The what age you can take Mounjaro page summarises these combined filters in one place, and our weight-loss treatments overview explains how different options compare for adults at different stages.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. Age-related factors are part of that clinical review, not afterthoughts. If you are ready to find out whether you are clinically suitable, speak to our prescribers through a free consultation, there is no obligation and no automatic outcome.